Back

Watch Compare

Oncotelic Therapeutics, Inc.

Data quality: 100%

OTLC

OTC Manufacturing Chemicals

$0.03

▼ $0.00 (-7.46%)

6 months return

—

Momentum

Neutral

5Y revenue growth

-55.22%

Growth

Revenue Growth (5Y)

-55.22%

Below sector avg (1.82%)

Revenue (1Y)0.00%

Earnings (1Y)N/A

FCF Growth (3Y)N/A

Quality

Return on Equity

-19.24%

Above sector avg (-54.47%)

ROIC-5.21%

Net MarginN/A

Op. MarginN/A

Safety

Debt / Equity

N/A

Current Ratio0.08

Interest CoverageN/A

Valuation

PE (TTM)

-10.61

Below sector avg (-1.49)

P/B Ratio1.96

EV/EBITDAN/A

Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Revenue declined -55.22% annually over 5 years

Negative free cash flow of -704,008.0

Revenue growth is accelerating — 1Y growth exceeds 5Y average by 55.22%

Price History

Financial Trends

Analyst Price Target

No analyst coverage available

Earnings Surprises

EPS

Reported Estimate

	Q42022	Q22023	Q32023
Reported	-$0.01	-$0.02	$0.00
Estimate	$0.00	$0.00	$0.00
Surprise	0.00%	0.00%	0.00%

Growth

Rev 5Y: -55.22% · Earnings 1Y: N/A

Revenue Growth (1Y)	0.00%	Revenue Growth (3Y)	N/A
Earnings Growth (1Y)	N/A	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	-55.22%	Earnings Growth (5Y)	N/A

Profitability

ROE: -19.24% · Net Margin: N/A

Revenue (TTM)	0.0	Net Income (TTM)	-1.67 M
ROE	-19.24%	ROA	-6.09%
Gross Margin	N/A	Operating Margin	N/A
Net Margin	N/A	Free Cash Flow (TTM)	-704,008.0
ROIC	-5.21%	FCF Growth (3Y)	N/A

Safety

D/E: N/A · Current: 0.08

Debt / Equity	N/A	Current Ratio	0.08
Interest Coverage	N/A	Asset Turnover	0.00
Working Capital	-18.47 M	Tangible Book Value	6.26 M

Dividends

Yield: N/A · Payout: N/A

Dividend Yield	N/A	Payout Ratio	N/A
Dividend Growth (3Y)	N/A	Dividend Growth (5Y)	N/A
Consecutive Div Years	N/A

Valuation

P/E: -10.61 · EV/EBITDA: N/A

P/E Ratio	-10.61	Forward P/E	N/A
P/B Ratio	1.96	P/S Ratio	N/A
PEG Ratio	N/A	Forward PEG	N/A
EV/EBITDA	N/A	Fwd EV/EBITDA	N/A
Forward P/S	N/A	Fwd Earnings Yield	N/A
FCF Yield	-3.98%
Market Cap	17.70 M	Enterprise Value	17.29 M

Per Share

EPS: N/A · FCF/Share: 0.00

EPS (Diluted TTM)	N/A	Revenue / Share	0.00
FCF / Share	0.00	OCF / Share	0.00
EPS CAGR (1Y)	N/A	EPS CAGR (5Y)	N/A
EPS CAGR (10Y)	N/A

Efficiency

FCF Conv: 42.18% · CapEx/Rev: N/A

CapEx / Revenue	N/A	FCF Conversion	42.18%
SBC-Adj. FCF	-887,750	Growth Momentum	55.22

Income Statement

Annual, most recent first

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	70,000.0	70,000.0	—	1.74 M	1.74 M
Net Income	-4.52 M	-7.90 M	5.09 M	-9.39 M	-9.50 M
EPS (Diluted)	—	-0.02	0.01	—	—
Gross Profit	—	—	—	—	—
Operating Income	-3.58 M	-6.65 M	-9.72 M	-9.13 M	-7.58 M
EBITDA	—	—	—	—	—
R&D Expenses	—	61,143.0	756,910.0	3.66 M	4.30 M
SG&A Expenses	—	—	—	—	—
D&A	—	—	—	—	—
Interest Expense	—	1.04 M	2.97 M	2.00 M	2.00 M
Income Tax	—	—	—	—	—

Balance Sheet

Annual, most recent first

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Total Assets	26.68 M	30.01 M	36.12 M	23.61 M	23.66 M
Total Liabilities	19.20 M	18.40 M	—	—	—
Shareholders' Equity	8.25 M	12.13 M	19.41 M	7.96 M	11.77 M
Total Debt	2.42 M	1.77 M	390,050.0	359,262.0	95,000.0
Cash & Equivalents	—	170,405.0	241,452.0	568,769.0	474,019.0
Current Assets	134,211.0	271,737.0	303,164.0	627,295.0	615,636.0
Current Liabilities	19.20 M	16.50 M	16.92 M	15.45 M	11.18 M

Peer Comparison

vs Manufacturing sector median (1605 peers)

Metric	Stock	Sector Median
P/E	-10.6	-1.5
P/B	2.0	1.6
ROE %	-19.2	-54.5
Net Margin %	—	-41.5
Rev Growth 5Y %	-55.2	1.8
D/E	—	0.3